Nexalis Therapeutics Limited (ASX:NX1)
Australia · Delayed Price · Currency is AUD 0.0090
-0.0010 (-10.00%)
At close: Sep 18, 2026
Nexalis Therapeutics Income Statement
Financials in millions AUD. Fiscal year is January - December.
Millions AUD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | - | - | - | - | 0.02 | 0.18 |
Other Revenue | 1.07 | 0.99 | 0.4 | 1.2 | - | - |
| 1.07 | 0.99 | 0.4 | 1.2 | 0.02 | 0.18 | |
Revenue Growth | 28.04% | 145.50% | -66.63% | 4755.02% | -86.35% | 721.35% |
Cost of Revenue | - | - | - | - | - | 0.12 |
Gross Profit | 1.07 | 0.99 | 0.4 | 1.2 | 0.02 | 0.07 |
Selling, General & Admin | 0.84 | 0.67 | 1.02 | 1.08 | 0.89 | 0.99 |
Research & Development | 2.03 | 1.76 | 0.62 | 1.45 | 0.98 | 0.12 |
Other Operating Expenses | 0.03 | 0.02 | 0.02 | 0.04 | 0.08 | 0.07 |
Operating Expenses | 2.93 | 2.47 | 1.68 | 2.63 | 1.98 | 1.18 |
Operating Income | -1.86 | -1.49 | -1.28 | -1.42 | -1.95 | -1.11 |
Interest Expense | -0.2 | -0.14 | -0.09 | -0.01 | - | - |
Interest & Investment Income | 0 | 0.01 | 0 | 0 | 0.02 | 0 |
Other Non Operating Income (Expenses) | - | - | 0.15 | - | - | - |
EBT Excluding Unusual Items | -2.06 | -1.62 | -1.21 | -1.43 | -1.94 | -1.11 |
Gain (Loss) on Sale of Assets | - | - | - | - | 0.01 | - |
Asset Writedown | - | - | - | -0.01 | - | - |
Pretax Income | -2.06 | -1.62 | -1.21 | -1.44 | -1.93 | -1.11 |
Earnings From Continuing Operations | -2.06 | -1.62 | -1.21 | -1.44 | -1.93 | -1.11 |
Net Income | -2.06 | -1.62 | -1.21 | -1.44 | -1.93 | -1.11 |
Net Income to Common | -2.06 | -1.62 | -1.21 | -1.44 | -1.93 | -1.11 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 234 | 216 | 213 | 189 | 173 | 168 |
Shares Outstanding (Diluted) | 234 | 216 | 213 | 189 | 173 | 168 |
Shares Change | 4.04% | 1.05% | 12.72% | 9.42% | 3.27% | 68.94% |
EPS (Basic) | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
EPS (Diluted) | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -0.78 | -0.89 | -0.37 | -1.96 | -1.85 | -1.16 |
Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.01 | -0.01 | -0.01 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 36.59% |
Operating Margin | -174.69% | -150.85% | -318.39% | -118.22% | -7879.43% | -611.57% |
Profit Margin | -193.63% | -164.10% | -300.98% | -119.87% | -7770.36% | -611.38% |
Free Cash Flow Margin | -73.68% | -90.04% | -91.78% | -162.94% | -7444.75% | -638.32% |
EBITDA | - | - | - | -1.41 | -1.94 | -1.11 |
EBITDA Margin | - | - | - | -117.42% | - | - |
D&A For EBITDA | - | - | - | 0.01 | 0.01 | 0 |
EBIT | -1.86 | -1.49 | -1.28 | -1.42 | -1.95 | -1.11 |
EBIT Margin | -174.69% | -150.85% | - | -118.22% | - | - |